Natera
NTRA
$271.39
+0.58%
Natera is a diagnostic and research company that leverages proprietary molecular and bioinformatics technology to develop non-invasive tests, including its Panorama Non-Invasive Prenatal Test (NIPT), Horizon Carrier Screening, Signatera molecular residual disease (MRD) test for cancer monitoring, and Prospera for organ transplant rejection assessment. As a leader in the liquid biopsy and reproductive health testing space, Natera differentiates itself through its advanced bioinformatics platform and a growing portfolio of FDA-cleared and laboratory-developed tests. The current investor narrative centers on the company's accelerating revenue growth driven by strong adoption of its Signatera MRD test in oncology, with recent quarterly revenue surging 38.8% year-over-year to $696.6 million, while the path to sustained profitability remains a key debate as the company continues to invest heavily in R&D and commercialization.…
NTRA
Natera
$271.39
Related headlines
Investment Opinion: Should I buy NTRA Today?
Rating: Hold. Natera is a high-growth diagnostics company with accelerating revenue and improving margins, but its premium valuation and continued losses limit upside potential. The consensus Strong Buy rating and average target of $279.76 suggest modest upside, but the risk/reward is balanced given the stock's proximity to its 52-week high.
Supporting Evidence: Natera's revenue grew 38.8% YoY to $696.6M, accelerating from 27.5% a year ago, and gross margins improved to 64.8%. The trailing PS of 13.6x is well above the industry average of 4.5x, but the forward PS of 5.6x is more reasonable if growth continues. Free cash flow turned positive at $18.0M, and the company has $1.09B in cash with low debt. Analyst targets imply 3.1% upside to the average and 21.6% to the high target of $330.
Risks & Conditions: The Hold rating would upgrade to Buy if the stock pulls back to a PS below 10x (around $200) or if the company achieves sustained profitability (positive net income). It would downgrade to Sell if revenue growth decelerates below 25% or if gross margins decline below 60%. The biggest risks are valuation compression and competitive pressures. Overall, Natera appears fairly valued relative to its growth rate but overvalued relative to industry peers, making it a hold for existing investors and a cautious buy on pullbacks.
Sign up to view all
NTRA 12-Month Price Forecast
Natera's strong revenue growth and improving margins are offset by a premium valuation that leaves little room for error. The base case of 30% growth and gradual margin improvement is most likely, suggesting the stock will trade near current levels. The bull case requires sustained acceleration and profitability, while the bear case hinges on competitive or reimbursement setbacks. Given the limited upside to the average target and the high volatility, a neutral stance is warranted. An upgrade to bullish would require evidence of accelerating growth and a clear path to profitability, while a downgrade would follow any signs of growth deceleration or margin compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $282.14 and implied upside of +4.0% versus the current price.
Average Target
$282.14
0 analysts
Implied Upside
+4.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$193 - $330
Analyst target range
Natera is covered by 21 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.5 on a 1-5 scale). The average price target is $279.76, implying approximately 3.1% upside from the current price of $271.39. The distribution leans heavily bullish, with no sell ratings and only one neutral rating (Goldman Sachs downgraded to Neutral in June 2026). The consensus reflects strong confidence in Natera's growth trajectory, particularly in oncology. The target range spans from a low of $193.00 to a high of $330.00. The high target of $330.00 assumes continued strong adoption of Signatera, potential FDA approvals, and margin expansion as the company scales. The low target of $193.00 prices in risks such as competitive pressure, slower-than-expected revenue growth, or a prolonged path to profitability. The spread of $137 (42% of the average target) indicates moderate uncertainty, typical for high-growth diagnostics stocks. Recent ratings actions show a mix: Canaccord Genuity, Morgan Stanley, Evercore, Guggenheim, Barclays, and BTIG have reiterated Buy/Overweight ratings in the past month, while Goldman Sachs downgraded from Buy to Neutral in June 2026, citing valuation concerns. This pattern suggests that while most analysts remain bullish, some caution is emerging at current levels.
Drowning in data?
Find the real signal!
Bulls vs Bears: NTRA Investment Factors
Natera presents a compelling growth story with accelerating revenue (38.8% YoY), improving margins, and a strong balance sheet. The bull case is anchored by the rapid adoption of Signatera in oncology and the company's leadership in liquid biopsy. However, the stock trades at a significant premium (13.6x PS vs. industry 4.5x) and still reports net losses, making it vulnerable to any growth deceleration. The most critical tension is whether Natera can sustain its 30%+ revenue growth trajectory long enough to justify its valuation. If growth continues to accelerate and profitability materializes, the stock could re-rate higher; if growth slows, multiple compression could erase gains. Currently, the evidence slightly favors the bulls given the strong momentum and improving fundamentals, but the limited upside to the average target suggests a balanced risk/reward.
Bullish
- Accelerating Revenue Growth: Revenue grew 38.8% YoY to $696.6M in Q1 2026, accelerating from 27.5% growth in Q1 2025. The multi-quarter trend shows consistent acceleration from 32.5% in Q2 2025 to 39.8% in Q4 2025, indicating strong market adoption of Signatera and other tests.
- Improving Profitability Metrics: Gross margin improved to 64.8% in Q1 2026 from 63.2% a year earlier, while operating margin improved from -20.2% in Q2 2025 to -13.4%. Free cash flow turned positive at $18.0M in Q1 2026, with TTM FCF of $92.0M, reducing reliance on external financing.
- Strong Balance Sheet: Natera holds $1.09B in cash with a current ratio of 3.39 and a low debt-to-equity ratio of 0.125. This provides ample liquidity to fund R&D and commercialization efforts without near-term financing risk.
- Bullish Analyst Consensus: 21 analysts rate the stock a Strong Buy (mean 1.5/5), with an average price target of $279.76 implying 3.1% upside. The high target of $330 suggests 21.6% potential upside, reflecting confidence in Signatera's growth trajectory.
Bearish
- High Valuation Premium: Trailing PS ratio of 13.6x is 202% above the industry average of ~4.5x. Even the forward PS of 5.6x implies aggressive growth expectations. Any growth disappointment could trigger multiple compression and significant downside.
- Continued Net Losses: Despite revenue growth, Natera reported a net loss of $85.1M in Q1 2026 (EPS -$0.6). While losses are narrowing, the company remains unprofitable, and the path to sustained profitability is uncertain given high R&D ($210.7M) and SG&A expenses.
- Limited Upside to Average Target: The average analyst target of $279.76 offers only 3.1% upside from the current price of $271.39. With the stock already near its 52-week high of $288.04, the risk/reward is skewed to the downside if growth decelerates.
- Goldman Sachs Downgrade: Goldman Sachs downgraded Natera from Buy to Neutral in June 2026, citing valuation concerns. This is the only neutral rating among 21 analysts, but it signals that some caution is warranted at current levels.
NTRA Technical Analysis
Natera is in a strong uptrend, with the stock price up 89.3% over the past year, significantly outperforming the S&P 500's 18.4% gain. The current price of $271.39 sits at 94.2% of its 52-week range (low $131.81, high $288.04), indicating the stock is trading near its highs and reflecting robust momentum. This positioning suggests bullish sentiment but also implies that the stock may be pricing in optimistic expectations, leaving limited room for error. Short-term momentum is exceptionally strong, with the stock gaining 19.9% over the past month and 30.2% over the past three months, both far exceeding the S&P 500's 0.3% and 4.7% returns, respectively. This acceleration in momentum relative to the longer-term trend signals a potential breakout phase, though the relative strength index (RSI) is not provided; the rapid ascent could lead to overbought conditions. The 1-month change of 19.9% is consistent with the 1-year uptrend, suggesting no divergence and reinforcing the bullish narrative. Key support lies near the 52-week low of $131.81, while resistance is at the 52-week high of $288.04. A breakout above $288.04 would signal a continuation of the uptrend, potentially targeting new highs, while a breakdown below $131.81 would indicate a reversal. With a beta of 1.505, Natera is 50.5% more volatile than the market, meaning larger price swings that require careful position sizing and risk management.
Beta
1.50
1.50x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$132-$288
Price range past year
Annual Return
+89.3%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | +19.9% | -0.5% |
| 3m | +30.2% | +4.9% |
| 6m | +17.4% | +9.7% |
| 1y | +89.3% | +18.4% |
| ytd | +18.6% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory is accelerating strongly, with Q1 2026 revenue of $696.6 million growing 38.8% year-over-year, up from 27.5% growth in Q1 2025 ($501.8 million). The sequential growth from Q4 2025's $665.5 million (4.7% quarter-over-quarter) indicates sustained momentum, driven primarily by the oncology segment (Signatera) and product revenue of $693.9 million. The multi-quarter trend shows accelerating growth: revenue grew 32.5% in Q2 2025, 34.7% in Q3 2025, and 39.8% in Q4 2025, suggesting the company is gaining market share in liquid biopsy and reproductive health. This robust growth supports the investment case, though investors should monitor whether the pace can be maintained as the base expands. Despite strong revenue growth, Natera remains unprofitable, with a net loss of $85.1 million in Q1 2026, though this loss narrowed from $100.9 million in Q2 2025. Gross margin improved to 64.8% in Q1 2026 from 63.2% in Q1 2025, reflecting better product mix and scale. Operating margin was -13.4%, improving from -20.2% in Q2 2025, indicating progress toward profitability. The company's net margin of -12.2% is typical for high-growth diagnostics firms investing heavily in R&D ($210.7 million in Q1 2026) and sales & marketing. Natera's balance sheet is solid, with $1.09 billion in cash and a current ratio of 3.39, indicating strong liquidity. The debt-to-equity ratio is low at 0.125, suggesting minimal financial risk. Free cash flow turned positive at $18.0 million in Q1 2026, a significant improvement from negative free cash flow in prior periods, and trailing twelve-month free cash flow is $92.0 million. ROE is negative (-12.2%) due to losses, but the improving cash flow generation reduces dependence on external financing. The FCF yield is not meaningful given negative earnings, but the cash position provides a cushion for continued investment.
Quarterly Revenue
$696644000.0B
2026-03
Revenue YoY Growth
+38.8%
YoY Comparison
Gross Margin
64.8%
Latest Quarter
Free Cash Flow
$92010000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Since Natera has negative net income (EPS of -$0.6 in Q1 2026), we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 13.6x, while the forward PS ratio (based on estimated revenue of $5.59 billion) is approximately 5.6x, implying the market expects significant revenue growth. The large gap between trailing and forward PS suggests aggressive growth expectations are already priced in. Compared to the Medical Diagnostics & Research industry average PS ratio of approximately 4.5x (estimated), Natera's trailing PS of 13.6x represents a 202% premium. This premium is partially justified by Natera's superior revenue growth (38.8% YoY vs. industry average of ~10-15%) and its leadership in high-growth liquid biopsy and NIPT markets. However, the premium is extreme and implies that any growth disappointment could lead to multiple compression. Historically, Natera's PS ratio has ranged from a low of 18.2x (in Q4 2022) to a high of 70.4x (in Q2 2021). The current trailing PS of 13.6x is near the lower end of its historical range, suggesting that despite the stock's rally, valuation is not stretched by historical standards. This could indicate that the market is still pricing in a recovery story, but investors should note that the historical PS range was set during periods of higher growth expectations and lower revenue bases. The current PS is below the 5-year average of ~30x, implying potential upside if growth continues to accelerate.
PE
-150.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-138.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Natera's primary financial risk is its continued unprofitability, with a net loss of $85.1M in Q1 2026 despite strong revenue growth. The company's operating margin of -13.4% indicates that operating expenses, particularly R&D ($210.7M) and SG&A ($327.9M), are outpacing gross profit. While free cash flow turned positive at $18.0M in Q1, the TTM FCF of $92.0M is modest relative to the $1.09B cash pile. The negative ROE of -12.2% and ROA of -9.1% reflect inefficiency in generating returns on equity and assets. Revenue concentration in oncology (Signatera) and reproductive health tests poses a risk if competition intensifies or reimbursement changes. The high PS ratio of 13.6x leaves little room for error; any revenue miss could lead to a sharp valuation correction.
Market & Competitive Risks: Natera faces intense competition in the liquid biopsy space from Guardant Health, Exact Sciences, and Grail, all of which have significant resources. The industry average PS of ~4.5x suggests that Natera's premium is extreme and could compress if growth slows. Regulatory risks include potential changes in FDA clearance requirements for laboratory-developed tests (LDTs) and reimbursement cuts from CMS or private payers. The stock's beta of 1.505 indicates high sensitivity to market downturns, and the recent Goldman Sachs downgrade to Neutral highlights valuation concerns. The short ratio of 3.66 suggests moderate bearish sentiment, and the stock's rapid 89.3% gain over the past year may attract profit-taking.
Worst-Case Scenario: In a worst-case scenario, Natera could face a combination of slowing revenue growth (e.g., below 20%), failure to achieve profitability, and competitive pressures leading to market share loss. This could trigger multiple compression, with the PS ratio falling toward the industry average of 4.5x. Applying a 5x PS to estimated FY2026 revenue of $5.59B yields a price of approximately $197, near the analyst low target of $193. From the current price of $271.39, this represents a downside of -27.4%. The 52-week low of $131.81 implies a potential loss of -51.4% if the worst-case materializes. Investors should monitor revenue growth rates and margin trends closely.
FAQ
The primary risk is valuation compression: at 13.6x PS, any growth deceleration could trigger a sharp de-rating toward the industry average of 4.5x, implying a potential 67% downside if multiples fully converge. Second, competitive risk from Guardant Health, Exact Sciences, and Grail in the liquid biopsy space could erode Natera's market share and pricing power. Third, regulatory and reimbursement risks: changes in FDA oversight of LDTs or CMS reimbursement cuts for NIPT or Signatera could impact revenue. Fourth, financial risk: the company remains unprofitable with a net loss of $85.1M in Q1 2026, and while free cash flow turned positive, sustained profitability is not guaranteed. The stock's high beta of 1.505 also means it is vulnerable to market downturns. The most severe risk is a combination of growth slowing below 20% and margin deterioration, which could drive the stock to the 52-week low of $131.81, a 51.4% decline from current levels.
Based on analyst targets and scenario analysis, the 12-month outlook for Natera is mixed. The base case (50% probability) assumes 28-32% revenue growth and gradual margin improvement, with the stock trading in a $250-$290 range, near the average target of $279.76. The bull case (25% probability) sees sustained 35%+ growth and potential FDA approvals, driving the stock to $290-$330 (high target $330). The bear case (25% probability) involves growth deceleration below 25% due to competition or reimbursement issues, with the stock falling to $190-$230 (low target $193). The most likely scenario is the base case, where the stock remains range-bound as investors weigh strong growth against a premium valuation. Key assumptions include revenue growth of 30% for FY2026 and gross margins around 65%.
Natera's trailing PS of 13.6x is 202% above the Medical Diagnostics & Research industry average of approximately 4.5x, indicating a significant premium. However, the forward PS of 5.6x based on estimated FY2026 revenue of $5.59B is more reasonable and reflects the market's expectation of continued strong growth. Historically, Natera's PS has ranged from 18.2x to 70.4x over the past five years, so the current level is below the historical average of ~30x, suggesting it is not stretched by its own history. The premium is partially justified by the company's superior growth rate (38.8% vs. industry 10-15%), but it leaves little room for error. Overall, Natera appears fairly valued relative to its growth trajectory but overvalued relative to peers, making it a stock that requires continued execution to justify its price.
Natera is a high-growth diagnostics company with accelerating revenue (38.8% YoY) and improving margins, but it trades at a premium valuation (13.6x PS vs. industry 4.5x) and is not yet profitable. The average analyst target of $279.76 implies only 3.1% upside, suggesting limited near-term appreciation. For long-term growth investors with a high risk tolerance, Natera could be a good buy on pullbacks, especially if the stock corrects to a PS below 10x. However, for value-oriented or income-focused investors, it is not suitable due to its losses and high valuation. The biggest downside risk is a growth deceleration leading to multiple compression, which could result in a 27% decline to the low target of $193.
Natera is better suited for long-term investment given its high growth trajectory and the multi-year opportunity in liquid biopsy and reproductive health. The company is still in the investment phase, with R&D spending of $210.7M in Q1 2026, and profitability may take several more quarters to achieve. Short-term trading is risky due to high volatility (beta 1.505) and the stock's proximity to its 52-week high, which could lead to pullbacks. The stock has no dividend, so total return depends entirely on price appreciation. A minimum holding period of 3-5 years is recommended to allow the growth story to play out and for the company to reach sustained profitability. For short-term traders, the stock's momentum could offer opportunities, but the risk of a sharp correction is significant given the premium valuation.
